Grey Matters Health (CSE:GREY, OTCQB:AGNPD, FRA:AGW0) CEO Christopher Moreau joined Stephen Gunnion to discuss plans to launch NovaScan brain PET imaging clinics in Florida, targeting growing demand for Alzheimer’s diagnostics and clinical trials. Moreau explained how PET imaging helps detect amyloid plaque linked to Alzheimer’s disease — something not possible with MRI or X-ray scans — making the technology increasingly important for diagnosis and treatment monitoring. The interview also covered Grey Matters Health’s LOI with Catalyst MedTech for at least 200 scans at its planned Tampa clinic, as pharmaceutical companies expand Alzheimer’s drug trials. Moreau highlighted the company’s CareMiBrain scanner, which allows patients to remain seated upright during scans while reducing radiation exposure by around 25%, offering what he described as a more comfortable alternative to traditional PET systems. Grey Matters Health plans to expand its specialist imaging clinic network across the US as demand for neurological diagnostics grows. For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel, and enable notifications for future content. #GreyMattersHealth #Alzheimers #BrainPETScan #PETImaging #NovaScan #ChristopherMoreau #HealthcareInnovation #ClinicalTrials #Biotech #MedicalImaging #Neurology #AlzheimersResearch #HealthcareStocks #ProactiveInvestors